CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOOS

Prostate Biopsy Specimen Analysis

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOOS alerts

Get alerted when Policy CPCPLABOOS changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Governs reimbursement and specimen handling/billing rules for pathological examination of prostate biopsy specimens for Blue Cross Blue Shield - Texas members; affects providers submitting claims for prostate biopsy pathology.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy CPCPLABOOS

Change TypeClarified specimen billing unitnon‑clinical revision

Effective DateSep 26, 2025

Last ReviewSep 26, 2025

Next Review Date

Key ActionLabel and submit prostate biopsy vials per guidance (one vial per sextant, maximum two cores per vial) and confirm product-specific coverage before billing.

SourceLink

POLICY UPDATE CHANGES

Added clarification that each vial, regardless of number of cores enclosed, is considered a single specimen for billing purposes.

Document updated with literature review; reimbursement information unchanged.

12-coreextended sampling referenced for initial diagnosis

one vial per sextantspecimen labeling/packing instruction

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOOS

Prostate Biopsy Specimen Analysis

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOOS alerts

Get alerted when Policy CPCPLABOOS changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy CPCPLABOOS

Change TypeClarified specimen billing unitnon‑clinical revision

Effective DateSep 26, 2025

Last ReviewSep 26, 2025

Next Review Date

Key ActionLabel and submit prostate biopsy vials per guidance (one vial per sextant, maximum two cores per vial) and confirm product-specific coverage before billing.

SourceLink

POLICY UPDATE CHANGES

Added clarification that each vial, regardless of number of cores enclosed, is considered a single specimen for billing purposes.

Document updated with literature review; reimbursement information unchanged.

12-coreextended sampling referenced for initial diagnosis

one vial per sextantspecimen labeling/packing instruction

not reimbursablesaturation biopsy coverage stance

01/03/2026plan effective date

Coverage Criteria

Medically necessary coverage

Covered when ALL of the following are met:

Initial diagnosis coverage: Pathological examination of tissue obtained from a prostate biopsy involving 12 core extended sampling may be reimbursable when performed as part of initial diagnosis following abnormal PSA, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.12 cores

See Note 1 for vial/unit rules

Repeat biopsy coverage: When clinical suspicion for prostate cancer remains after an initial negative prostate biopsy, pathological examination of tissue from a follow-up prostate biopsy may be reimbursable.exclude saturation biopsy

Saturation biopsy not reimbursable

Non-reimbursable procedure: Pathological examination of tissue obtained from a prostate saturation biopsy is not reimbursable for the diagnosis, staging, or management of prostate cancer.

Specimen handling and billing: Specimens must be submitted with one vial per sextant and no more than two core samples per vial. Each vial, regardless of the number of cores enclosed, is considered a single specimen for billing purposes.

Pathological examination of tissue obtained from a prostate saturation biopsy is not reimbursable for the diagnosis, staging, or management of prostate cancer.

Saturation prostate biopsy pathology is considered not medically necessary and therefore not reimbursable for diagnosis, staging, or management of prostate cancer.

Coding and Specimen Handling

Procedure Codes (not exhaustive)mixed

No codes listed

Covered CPT CodesCPTCovered

No codes listed

Not Covered CodesmixedNot Covered

No codes listed

Experimental / Investigational CodesmixedExperimental

No codes listed

Cores per vial — specimen handling and billing

Cores per vialNo more than two core samples per vial; each vial (regardless of number of cores) is considered a single specimen for billing.

Vial packing instructionOne vial per sextant.

Billing unit clarificationEach vial is considered a single specimen for billing purposes even if multiple cores are enclosed.

Provider Actions and Billing Requirements

Prior Authorization

Check product-specific coverage

Verify product-specific coverage and any plan-specific laboratory management or reimbursement criteria before ordering or billing. Plan documents (Certificates of Coverage, benefit booklets, Summary Plan Descriptions, and other coverage documents) govern when they conflict with this policy.

Not all lab management requirements apply to each product — check the member's plan for eligibility and coverage rules.
If a conflict exists between this Clinical Payment and Coding Policy and the member's plan document, the plan document governs.
Providers may need to follow plan-specific specimen handling or billing rules when submitting claims.

Documentation Required

Accurate coding and documentation required

Providers must submit accurate, complete documentation and code claims according to standard coding systems (CPT, HCPCS, ICD-10, NDC, DRG) and industry coding guidelines. If documentation is requested during claim review, promptly provide supporting records.

Background

The primary purpose of pathologic examination of prostate biopsy tissue is to establish or exclude a diagnosis of prostate cancer following abnormal screening or clinical findings. Extended 12‑core sampling may be reimbursable when performed as part of the initial diagnostic evaluation after an abnormal PSA, a palpable nodule on digital rectal examination, or suspicious radiologic findings. Repeat biopsies may be reimbursable when clinical suspicion persists after a negative initial biopsy, but pathology for saturation prostate biopsy is not reimbursable. Specimen handling guidance: submit one vial per sextant with no more than two core samples per vial; each vial is considered a single specimen for billing.

Definitions

Saturation prostate biopsy — definition and coverage stance

TermProstate saturation biopsy

DefinitionA high-core-count prostate biopsy technique; pathological examination of tissue obtained from a prostate saturation biopsy is not reimbursable for the diagnosis, staging, and management of prostate cancer.

Coverage stanceNot reimbursable (not medically necessary) for diagnosis, staging, or management.

Extended 12-core prostate biopsy — definition

TermExtended 12-core prostate biopsy

DefinitionAn extended 12-core sampling method referenced as an acceptable sampling approach for initial diagnosis following abnormal PSA, palpable nodule on DRE, or suspicious radiologic findings.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy CPCPLABOOS

Change TypeClarified specimen billing unitnon‑clinical revision

Effective DateSep 26, 2025

Last ReviewSep 26, 2025

Next Review Date

Key ActionLabel and submit prostate biopsy vials per guidance (one vial per sextant, maximum two cores per vial) and confirm product-specific coverage before billing.

SourceLink

On This Page

Claims are subject to claim review and code edit protocols; reimbursement may be adjusted or denied if documentation or coding is incomplete or incorrect.
Use Health Insurance Portability and Accountability Act–approved code sets and adhere to Uniform Billing Editor, AMA CPT resources, CMS NCCI edits, and related guidance.
Upon request, submit additional documentation to support medical necessity and the services billed.

Documentation Required

Required documentation and specimen labeling for prostate biopsy

For prostate biopsy specimens, document clinical indication and follow the specimen labeling and submission expectations: one vial per sextant, with no more than two core samples per vial. Each vial is considered a single specimen for billing regardless of number of cores enclosed.

Indicate clinical reason (e.g., elevated PSA, palpable nodule on DRE, suspicious imaging) on pathology requisition and in the medical record.
Label each vial by sextant and ensure specimen source, date/time, and patient identifiers are present.
Do not combine more than two cores per vial; billing treats each vial as one specimen.

Denial Risk

Claim review and denial risk

Claims for prostate biopsy pathology are reimbursable only when submitted in accordance with clinical and billing rules; there is denial risk for procedures not meeting criteria (for example, prostate saturation biopsy) or lacking proper documentation.

Pathology for initial 12-core extended prostate biopsy may be reimbursable when indicated by abnormal PSA, palpable nodule, or suspicious imaging.
Follow-up prostate biopsy pathology (excluding saturation biopsy) may be reimbursable if clinical suspicion persists after a negative initial biopsy.
Pathological examination of tissue from a prostate saturation biopsy is not reimbursable for diagnosis, staging, or management of prostate cancer.
Failure to follow plan-specific lab management reimbursement criteria or to provide requested documentation can result in claim denial or recoupment.

Reimbursement notePathological examination of tissue from a 12-core extended sampling may be reimbursable when performed as part of initial diagnosis.